Related Experiment Video
Updated: May 3, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Research Burden in Pediatric Cancer: A Mixed Methods Study From the PediQUEST Response Trial.
Erika Tsuchiyose1, Deborah Feifer2, Alexandra F Merz3
1Tufts University School of Medicine (E.T.), Boston, Massachusetts, USA.
Study burden in pediatric advanced cancer trials is often low to moderate. However, families facing social disparities, including historically marginalized (HM) or economic hardship (EH) backgrounds, experience significantly higher burdens.
Area of Science:
- Pediatric Oncology
- Clinical Trial Research
- Health Disparities
Background:
- The research burden on families with children in advanced cancer studies is not well understood.
- Understanding this burden is crucial for improving trial participation and support.
Purpose of the Study:
- To assess study-related burden in parents and children within the PediQUEST Response Trial.
- To investigate factors associated with this burden, specifically focusing on historically marginalized (HM) and economic hardship (EH) statuses.
Main Methods:
- A mixed-methods secondary analysis of data from a randomized controlled trial (RCT) involving 154 dyads.
- Thematic analysis of parent and child interviews identified burden sources.
- A six-level burden variable integrated qualitative data and quantitative dropout status.
- Ordinal logistic regression explored associations between social disparities (HM/EH) and burden levels.
Main Results:
- Most families reported low to moderate burden (levels 0-3), with approximately 20% experiencing high burden (levels 4-5).
- Parental burden significantly increased with greater social disparity (cumulative ORs 2.3-4.9).
- No significant association was found between social disparity and child's study burden.
Conclusions:
- While overall study burden is manageable, social disparities exacerbate it for parents in pediatric advanced cancer trials.
- Developing targeted support strategies is essential to enhance diversity and inclusivity in pediatric cancer research.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
08:34Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Related Concept Videos
Bioavailability Study Design: Healthy Subjects Versus Patients
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Excretion